The rotation into health care highlights a strategic shift among traders seeking shelter from the volatility of inflation-sensitive sectors. Eli Lilly remains the focal point of this momentum, fueled by consistent market confidence in the long-term sales potential of its obesity treatments.

Corporate strategy is already shifting to accommodate the rise of these medications. Food processing giant Nestle is actively retooling its product lines, planning to enhance flavors to appeal to consumers whose sensory experiences change while using GLP-1 weight-loss drugs.